Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

156 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.
Sonneveld P, Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, Salwender H, Zweegman S, Vellenga E, Broyl A, Blau IW, Weisel KC, Wittebol S, Bos GM, Stevens-Kroef M, Scheid C, Pfreundschuh M, Hose D, Jauch A, van der Velde H, Raymakers R, Schaafsma MR, Kersten MJ, van Marwijk-Kooy M, Duehrsen U, Lindemann W, Wijermans PW, Lokhorst HM, Goldschmidt HM. Sonneveld P, et al. Among authors: raymakers r. J Clin Oncol. 2012 Aug 20;30(24):2946-55. doi: 10.1200/JCO.2011.39.6820. Epub 2012 Jul 16. J Clin Oncol. 2012. PMID: 22802322 Free article. Clinical Trial.
Partially T-cell-depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: a prospective evaluation of patients treated in the phase III study HOVON 24 MM.
Lokhorst HM, Segeren CM, Verdonck LF, van der Holt B, Raymakers R, van Oers MH, Barge RM, Schouten HC, Westveer PH, Steijaert MM, Cornelissen JJ, Sonneveld P; Dutch-Belgian Hemato-Oncology Cooperative Group. Lokhorst HM, et al. Among authors: raymakers r. J Clin Oncol. 2003 May 1;21(9):1728-33. doi: 10.1200/JCO.2003.04.033. J Clin Oncol. 2003. PMID: 12721248 Clinical Trial.
Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operative Trial Group for Hematology Oncology.
Hazenberg BP, Croockewit A, van der Holt B, Zweegman S, Bos GM, Delforge M, Raymakers RA, Sonneveld P, Vellenga E, Wijermans PW, von dem Borne PA, van Oers MH, de Weerdt O, Spoelstra FM, Lokhorst HM; Dutch-Belgian Cooperative Trial Group for Hematology Oncology. Hazenberg BP, et al. Haematologica. 2015 May;100(5):677-82. doi: 10.3324/haematol.2014.119198. Epub 2015 Feb 6. Haematologica. 2015. PMID: 25661441 Free PMC article. Clinical Trial.
Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial.
Goldschmidt H, Lokhorst HM, Mai EK, van der Holt B, Blau IW, Zweegman S, Weisel KC, Vellenga E, Pfreundschuh M, Kersten MJ, Scheid C, Croockewit S, Raymakers R, Hose D, Potamianou A, Jauch A, Hillengass J, Stevens-Kroef M, Raab MS, Broijl A, Lindemann HW, Bos GMJ, Brossart P, van Marwijk Kooy M, Ypma P, Duehrsen U, Schaafsma RM, Bertsch U, Hielscher T, Jarari L, Salwender HJ, Sonneveld P. Goldschmidt H, et al. Among authors: raymakers r. Leukemia. 2018 Feb;32(2):383-390. doi: 10.1038/leu.2017.211. Epub 2017 Jul 4. Leukemia. 2018. PMID: 28761118 Clinical Trial.
Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study.
Lokhorst HM, van der Holt B, Cornelissen JJ, Kersten MJ, van Oers M, Raymakers R, Minnema MC, Zweegman S, Janssen JJ, Zijlmans M, Bos G, Schaap N, Wittebol S, de Weerdt O, Ammerlaan R, Sonneveld P. Lokhorst HM, et al. Among authors: raymakers r. Blood. 2012 Jun 28;119(26):6219-25; quiz 6399. doi: 10.1182/blood-2011-11-393801. Epub 2012 Mar 22. Blood. 2012. PMID: 22442350 Free article. Clinical Trial.
Reduced relapse rate in upfront tandem autologous/reduced-intensity allogeneic transplantation in multiple myeloma only results in borderline non-significant prolongation of progression-free but not overall survival.
Lokhorst HM, van der Holt B, Cornelissen JJ, Kersten MJ, van Oers M, Raymakers R, Minnema MC, Zweegman S, Bos G, Schaap N, Wittebol S, de Weerdt O, Ammerlaan R, Sonneveld P. Lokhorst HM, et al. Among authors: raymakers r. Haematologica. 2015 Dec;100(12):e508-10. doi: 10.3324/haematol.2015.128728. Epub 2015 Sep 4. Haematologica. 2015. PMID: 26341740 Free PMC article. Clinical Trial. No abstract available.
Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma.
Nijhof IS, Franssen LE, Levin MD, Bos GMJ, Broijl A, Klein SK, Koene HR, Bloem AC, Beeker A, Faber LM, van der Spek E, Ypma PF, Raymakers R, van Spronsen DJ, Westerweel PE, Oostvogels R, van Velzen J, van Kessel B, Mutis T, Sonneveld P, Zweegman S, Lokhorst HM, van de Donk NWCJ. Nijhof IS, et al. Among authors: raymakers r. Blood. 2016 Nov 10;128(19):2297-2306. doi: 10.1182/blood-2016-07-729236. Epub 2016 Sep 19. Blood. 2016. PMID: 27647864 Free article. Clinical Trial.
Analysis of efficacy and prognostic factors of lenalidomide treatment as part of a Dutch compassionate use program.
Kneppers E, Lokhorst HM, Eeltink CM, Huls G, Kersten MJ, Koedam J, Minnema MC, van Oers MH, Raymakers RA, Schaafsma MR, Vellenga E, Wijermans PW, Wittebol S, Sonneveld P, Zweegman S. Kneppers E, et al. Among authors: raymakers ra. Clin Lymphoma Myeloma Leuk. 2010 Apr;10(2):138-43. doi: 10.3816/CLML.2010.n.020. Clin Lymphoma Myeloma Leuk. 2010. PMID: 20371448
156 results